Skip to main content
. Author manuscript; available in PMC: 2022 Mar 4.
Published in final edited form as: Clin Cancer Res. 2021 May 4;27(13):3734–3743. doi: 10.1158/1078-0432.CCR-20-5037

Figure 1:

Figure 1:

Landscape of germline and somatic mutations and copy number alterations of HR genes across the three bladder cancer WES cohorts. We identified 4 BRCA2-deficient samples, 3 BRCA1-deficient samples, 2 RBBP8-deficient samples, and 1 BARD1-deficient sample in the three cohorts.